Cambridge company recognized for potential Celiac-curing vaccine

ImmusanT Inc., the Cambridge company that is developing a vaccine that would allow people with Celiac disease to eat gluten, has received some important recognition. Informa has named the company's drug one of the Top 10 Autoimmune/Anti-Inflammatory Projects to Watch. That has given new energy to ImmusanT executives as they enter Phase 2 of clinical trials. One percent of the world's population has Celiac disease, an autoimmune disorder that triggers a defensive response to gluten. "We believeā€¦
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news